GAL401

GAL401 is an investigational adeno-associated virus (AAV)-based gene therapy being developed by Galibra Neuroscience for the treatment of drug-resistant epilepsy (DRE). The therapy is designed to utilize an AAV vector to deliver genetic material targeting GABAergic mechanisms, aiming to restore the balance between excitatory and inhibitory neurotransmission in the brain. While the specific molecular target for GAL401 has not been publicly disclosed, the program has demonstrated proof-of-concept in vivo. It is currently in the discovery stage of development as part of a pipeline focused on GABA-related neurologic conditions.